Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 3 3Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Cardiovascular Diseases 1

Interventions

Cyclophosphamide 171Docetaxel 164Paclitaxel 160Trastuzumab 152Capecitabine 130Tamoxifen 119Letrozole 105Epirubicin 93Doxorubicin 83Anastrozole 83exemestane 77Fulvestrant 75Carboplatin 64Fluorouracil 63Radiotherapy 61pertuzumab 59Gemcitabine 55Vinorelbine 43Goserelin 39eribulin 36130-nm albumin-bound paclitaxel 36palbociclib 32Bevacizumab 32ribociclib 30Zoledronic Acid 29Lapatinib 29Methotrexate 28Drug Therapy 28Chemotherapy, Adjuvant 28Ado-Trastuzumab Emtansine 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Raloxifene Hydrochloride × Breast × Clear all
NCT00687102 2018-09-12

Co-STAR

Wake Forest University Health Sciences

Phase 3 Completed
1,498 enrolled 13 charts
Breast

Breast Neoplasms

NCT00003906 2015-10-06

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

NSABP Foundation Inc

Phase 3 Completed
19,747 enrolled
Breast

Breast Neoplasms

NCT00190593 2007-01-26

Raloxifene Use for The Heart

Eli Lilly and Company

Phase 3 Completed
10,000 enrolled
Breast

Breast Neoplasms, Cardiovascular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡